MA28883B1 - Procede de preparation de 4-{4-[({[4-chloro-3-(trifluoromethyl) phenyl]amino}carbonyl) amino]phenoxy}-n-methylpyridine-2-carboxamide - Google Patents

Procede de preparation de 4-{4-[({[4-chloro-3-(trifluoromethyl) phenyl]amino}carbonyl) amino]phenoxy}-n-methylpyridine-2-carboxamide

Info

Publication number: MA28883B1
Authority: MA; Morocco
Prior art keywords: amino; methylpyridine; carboxamide; phenoxy; trifluoromethyl
Prior art date: 2004-09-29

Application number

MA29788A

Other languages

English (en)

Inventor

Michael Loegers

Reinhold Gehring

Oliver Kuhn

Mike Matthaeus

Klaus Mohrs

Matthias Mueller-Gliemann

Juergen Stiehl

Mathias Berwe

Jana Lenz

Werner Heilmann

Original Assignee

Bayer Schering Pharma Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-09-29

Filing date

2007-03-30

Publication date

2007-09-03

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35457568&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA28883(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2007-03-30 Application filed by Bayer Schering Pharma Ag filed Critical Bayer Schering Pharma Ag

2007-09-03 Publication of MA28883B1 publication Critical patent/MA28883B1/fr

Links

MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 title 1
238000004519 manufacturing process Methods 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Epidemiology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Pyridine Compounds (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Developing Agents For Electrophotography (AREA)
Coloring Foods And Improving Nutritive Qualities (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines Containing Plant Substances (AREA)

MA29788A 2004-09-29 2007-03-30 Procede de preparation de 4-{4-[({[4-chloro-3-(trifluoromethyl) phenyl]amino}carbonyl) amino]phenoxy}-n-methylpyridine-2-carboxamide MA28883B1 (fr)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
EP04023131		2004-09-29

Publications (1)

Publication Number	Publication Date
MA28883B1 true MA28883B1 (fr)	2007-09-03

Family

ID=35457568

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MA29788A MA28883B1 (fr)	2004-09-29	2007-03-30	Procede de preparation de 4-{4-[({[4-chloro-3-(trifluoromethyl) phenyl]amino}carbonyl) amino]phenoxy}-n-methylpyridine-2-carboxamide

Country Status (34)

Country	Link
US (1)	US8124782B2 (fr)
EP (1)	EP1797037B1 (fr)
JP (2)	JP2008514657A (fr)
KR (1)	KR101263032B1 (fr)
CN (1)	CN101052619B (fr)
AR (1)	AR053973A1 (fr)
AU (1)	AU2005289099B2 (fr)
BR (1)	BRPI0515944B1 (fr)
CA (1)	CA2581835C (fr)
CU (1)	CU23754B7 (fr)
CY (1)	CY1116126T1 (fr)
DK (1)	DK1797037T3 (fr)
DO (1)	DOP2005000183A (fr)
EC (1)	ECSP077357A (fr)
ES (1)	ES2532377T3 (fr)
GT (1)	GT200500269A (fr)
HN (1)	HN2005000768A (fr)
HR (1)	HRP20150295T1 (fr)
IL (1)	IL182046A0 (fr)
MA (1)	MA28883B1 (fr)
MY (1)	MY149873A (fr)
NO (1)	NO339647B1 (fr)
NZ (1)	NZ554119A (fr)
PE (5)	PE20091587A1 (fr)
PL (1)	PL1797037T3 (fr)
PT (1)	PT1797037E (fr)
SG (1)	SG155997A1 (fr)
SI (1)	SI1797037T1 (fr)
SV (1)	SV2006002243A (fr)
TW (1)	TWI382973B (fr)
UA (1)	UA90691C2 (fr)
UY (1)	UY29143A1 (fr)
WO (1)	WO2006034796A1 (fr)
ZA (1)	ZA200702511B (fr)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
CA2359244C (fr)	1999-01-13	2013-10-08	Bayer Healthcare Llc	Diphenyle urees a substitution .omega.-carboxy aryle en tant qu'inhibiteurs de la kinase p38
US8124630B2 (en)	1999-01-13	2012-02-28	Bayer Healthcare Llc	ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
EP2324825A1 (fr)	2002-02-11	2011-05-25	Bayer Healthcare LLC	Arylurées dotées d'une activité d'inhibition de l'angiogenèse
DE602004007382T2 (de)	2003-05-20	2008-04-17	Bayer Pharmaceuticals Corp., West Haven	Diaryl-harnstoffe für durch pdgfr vermittelte krankheiten
DK1663978T3 (da)	2003-07-23	2008-04-07	Bayer Pharmaceuticals Corp	Fluorsubstitueret omega-carboxyaryl-diphenylurinstof til behandling og forebyggelse af sygdomme og lidelser
SG155997A1 (en)	2004-09-29	2009-10-29	Bayer Schering Pharma Ag	Process for the preparation of 4-{4-[({[4-chloro-3- (trifluoromethyl)phenyl]amino}carbonyl)amino]phenoxy}-n- methylpyridine-2-carboxamide
WO2006034797A1 (fr)	2004-09-29	2006-04-06	Bayer Healthcare Ag	Forme thermodynamiquement stable de tosylate de bay 43-9006
KR101335932B1 (ko)	2005-03-07	2013-12-04	바이엘 헬스케어 엘엘씨	암의 치료를 위한 오메가-카르복시아릴 치환된 디페닐우레아를 포함하는 제약 조성물
AR062927A1 (es)	2006-10-11	2008-12-17	Bayer Healthcare Ag	4- [4-( [ [ 4- cloro-3-( trifluorometil) fenil) carbamoil] amino] -3- fluorofenoxi) -n- metilpiridin-2- carboxamida monohidratada
US20100113533A1 (en) *	2006-11-14	2010-05-06	Bayer Schering Pharma Aktiengesellschaft	Polymorph II of 4-[4-(Amino)-3- Fluorophenoxy]-N-Methylpyridine-2-Carboxamide
KR101553211B1 (ko) *	2007-09-10	2015-09-15	씨아이피엘에이 엘티디.	Ｒａｆ 키나아제 저해제의 제조방법 및 상기 제조방법에 사용되는 중간체
WO2009054004A2 (fr) *	2007-10-22	2009-04-30	Natco Pharma Limited	Nouveau procédé pour la préparation du sorafénib
EP2231612A1 (fr)	2008-01-17	2010-09-29	Sicor, Inc.	Polymorphes de forme iii de tosylate de sorafénib, solvate de méthanol tosylate de sorafénib et solvate d'éthanol tosylate de sorafénib, et procédés de préparation associés
EP2142507A1 (fr) *	2008-03-06	2010-01-13	Sicor, Inc.	Procédé de préparation du sorafénib et ses sels
CN103254126A (zh) *	2008-09-19	2013-08-21	苏州泽璟生物制药有限公司	氘代的ω-二苯基脲及衍生物以及包含该化合物的药物组合物
US8604208B2 (en)	2009-09-24	2013-12-10	Ranbaxy Laboratories Limited	Polymorphs of sorafenib acid addition salts
EP2480534A1 (fr) *	2009-09-24	2012-08-01	Ranbaxy Laboratories Limited	Procédé de préparation de tosylate de sorafénib
WO2011058522A1 (fr)	2009-11-12	2011-05-19	Ranbaxy Laboratories Limited	Sel d'ethylsulfonate de sorafenib et son procede de preparation
WO2011076711A2 (fr)	2009-12-23	2011-06-30	Ratiopharm Gmbh	Polymorphes de 4-[4-[[4-chloro-3-(trifluorométhyl)phényl]carbamoylamino]phénoxy]-n-méthylpyridine-2-carboxamide
EP2528899B1 (fr)	2010-01-29	2014-10-15	Ranbaxy Laboratories Limited	Solvate de diméthylsulfoxyde du sorafenib
CN102190616B (zh) *	2010-03-18	2015-07-29	苏州泽璟生物制药有限公司	一种氘代的ω-二苯基脲的合成及生产的方法和工艺
AR081060A1 (es)	2010-04-15	2012-06-06	Bayer Schering Pharma Ag	Procedimiento para preparar 4-{4-[({[4-cloro-3-(trifluorometil)fenil]amino}carbonil)amino]-3-fluorofenoxi}-n-metilpiridin-2-carboxamida
CN102617458A (zh) *	2010-05-18	2012-08-01	张南	抗癌用化合物的制备方法
EP2595628A1 (fr)	2010-07-19	2013-05-29	Bayer HealthCare LLC	Associations médicamenteuses contenant une oméga-carboxyaryl diphénylurée fluorosubstituée utilisées pour le traitement et la prévention de maladies et d'affections
EP2621486A1 (fr)	2010-10-01	2013-08-07	Bayer Intellectual Property GmbH	Combinaisons contenant du n-(2-arylamino)arylsulfonamide substitué
WO2012071425A1 (fr)	2010-11-22	2012-05-31	Teva Pharmaceutical Industries Ltd.	Formes à l'état solide de bésylate de sorafénib et procédés de préparation
EP2559431A1 (fr)	2011-08-17	2013-02-20	Ratiopharm GmbH	Composition pharmaceutique comportant du 4-[4-[[4-Chloro-3-(trifluoromethyl)phényl]carbamoylamino]phénoxy]-N-méthyl-pyridine-2-carboxamide
CN103664771B (zh) *	2012-09-19	2016-03-30	齐鲁制药有限公司	索拉非尼的晶型a及其制备方法
WO2014118807A1 (fr) *	2013-02-04	2014-08-07	Intas Pharmaceuticals Limited	Nouveau procédé de préparation de tosylate de sorafénib de forme iii
CN104710354A (zh) *	2013-12-13	2015-06-17	江苏豪森药业股份有限公司	高纯度索拉非尼的制备方法
CN104761492A (zh) *	2014-01-03	2015-07-08	正大天晴药业集团股份有限公司	对甲苯磺酸索拉非尼的晶型及其制备方法
CN104177292A (zh) *	2014-08-08	2014-12-03	亿腾药业（泰州）有限公司	一种工业化生产甲苯磺酸索拉非尼多晶型ⅰ的方法
CN110204483B (zh) *	2014-12-01	2021-06-29	石药集团中奇制药技术（石家庄）有限公司	一种甲苯磺酸索拉非尼新晶型及其制备方法
EP3109236B1 (fr)	2015-06-23	2017-08-09	F.I.S.- Fabbrica Italiana Sintetici S.p.A.	Procédé évolutif pour la préparation de solvate d'éthanol tosylate de sorafénibe et tosylate de sorafénibe forme iii
CN105181844A (zh) *	2015-09-11	2015-12-23	江苏嘉逸医药有限公司	一种高效液相色谱法测定甲苯磺酸索拉非尼含量和有关物质的方法
CN105585523A (zh) *	2015-12-29	2016-05-18	上海北卡医药技术有限公司	一种对甲苯磺酸索拉非尼的新晶型及其制备方法和用途
CN107840823B (zh) *	2016-09-20	2021-08-17	意大利合成制造有限公司	用于制备甲苯磺酸索拉非尼乙醇溶剂化物和iii型甲苯磺酸索拉非尼的可变规模的方法
CN107915676A (zh) *	2017-10-26	2018-04-17	魏海霞	索拉非尼的制备方法
CN109796400B (zh) *	2017-11-16	2022-07-29	四川科伦药物研究院有限公司	一种甲苯磺酸索拉菲尼晶型及其制备方法
CN113773249A (zh) *	2020-06-10	2021-12-10	杭州中美华东制药有限公司	索拉非尼游离碱晶型Form X及其制备方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
LU86960A1 (fr) *	1987-07-31	1989-03-08	Oreal	Procede de preparation de piperidino-6 diamino-2,4 pyrimidine oxyde-3 et composes nouveaux
JPH02934A (ja) *	1988-05-27	1990-01-05	Konica Corp	非線形光学材料
JP2971291B2 (ja) *	1993-06-02	1999-11-02	田辺製薬株式会社	光学活性２−アミノ酪酸の製法
JP3866323B2 (ja) *	1996-03-27	2007-01-10	ポーラ化成工業株式会社	新規ｎ−ベンジルベンズアミド誘導体
JPH09316069A (ja) *	1996-03-28	1997-12-09	Ajinomoto Co Inc	新規キサントン誘導体
EP1140840B1 (fr)	1999-01-13	2006-03-22	Bayer Pharmaceuticals Corp.	Diphenylurees a substituants -g(v)-carboxyaryles, inhibitrices de kinase raf
US8124630B2 (en)	1999-01-13	2012-02-28	Bayer Healthcare Llc	ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
PT1690853E (pt) *	1999-01-13	2010-04-23	Bayer Healthcare Llc	Difenilureias substituídas com w-carboxiarilo como inibidores de raf-quinase
GB2367816A (en) *	2000-10-09	2002-04-17	Bayer Ag	Urea- and thiourea-containing derivatives of beta-amino acids
AU2002351196A1 (en)	2001-12-03	2003-06-17	Bayer Pharmaceuticals Corporation	Aryl urea compounds in combination with other cytostatic or cytotoxic agents for treating human cancers
US20030207872A1 (en) *	2002-01-11	2003-11-06	Bayer Corporation	Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
DE10203086A1 (de) *	2002-01-28	2003-07-31	Bayer Ag	5-Ring Heterozyklen
EP2324825A1 (fr) *	2002-02-11	2011-05-25	Bayer Healthcare LLC	Arylurées dotées d'une activité d'inhibition de l'angiogenèse
EP1842852A1 (fr) *	2002-08-13	2007-10-10	Sandoz AG	Un intermediaire de cefdinir
JP3763414B2 (ja) *	2002-10-21	2006-04-05	麒麟麦酒株式会社	Ｎ−｛２−クロロ−４−［（６，７−ジメトキシ−４−キノリル）オキシ］フェニル｝−ｎ’−（５−メチル−３−イソキサゾリル）ウレアの塩の結晶形
DE602004007382T2 (de)	2003-05-20	2008-04-17	Bayer Pharmaceuticals Corp., West Haven	Diaryl-harnstoffe für durch pdgfr vermittelte krankheiten
SG155997A1 (en)	2004-09-29	2009-10-29	Bayer Schering Pharma Ag	Process for the preparation of 4-{4-[({[4-chloro-3- (trifluoromethyl)phenyl]amino}carbonyl)amino]phenoxy}-n- methylpyridine-2-carboxamide

2005
- 2005-09-20 SG SG200906449-4A patent/SG155997A1/en unknown
- 2005-09-20 BR BRPI0515944-0A patent/BRPI0515944B1/pt active IP Right Grant
- 2005-09-20 SI SI200531947T patent/SI1797037T1/sl unknown
- 2005-09-20 PL PL05794785T patent/PL1797037T3/pl unknown
- 2005-09-20 US US11/664,332 patent/US8124782B2/en active Active
- 2005-09-20 CA CA2581835A patent/CA2581835C/fr not_active Expired - Lifetime
- 2005-09-20 HR HRP20150295TT patent/HRP20150295T1/hr unknown
- 2005-09-20 ES ES05794785.5T patent/ES2532377T3/es not_active Expired - Lifetime
- 2005-09-20 AU AU2005289099A patent/AU2005289099B2/en not_active Ceased
- 2005-09-20 CN CN2005800373684A patent/CN101052619B/zh not_active Expired - Lifetime
- 2005-09-20 KR KR1020077009652A patent/KR101263032B1/ko not_active Expired - Fee Related
- 2005-09-20 JP JP2007533904A patent/JP2008514657A/ja active Pending
- 2005-09-20 PT PT05794785T patent/PT1797037E/pt unknown
- 2005-09-20 NZ NZ554119A patent/NZ554119A/en not_active IP Right Cessation
- 2005-09-20 UA UAA200704750A patent/UA90691C2/ru unknown
- 2005-09-20 WO PCT/EP2005/010118 patent/WO2006034796A1/fr not_active Ceased
- 2005-09-20 DK DK05794785T patent/DK1797037T3/en active
- 2005-09-20 EP EP05794785.5A patent/EP1797037B1/fr not_active Expired - Lifetime
- 2005-09-23 DO DO2005000183A patent/DOP2005000183A/es unknown
- 2005-09-26 AR ARP050104020A patent/AR053973A1/es active IP Right Grant
- 2005-09-27 MY MYPI20054553A patent/MY149873A/en unknown
- 2005-09-28 TW TW094133620A patent/TWI382973B/zh not_active IP Right Cessation
- 2005-09-28 PE PE2009000512A patent/PE20091587A1/es active IP Right Grant
- 2005-09-28 UY UY29143A patent/UY29143A1/es not_active IP Right Cessation
- 2005-09-28 PE PE2005001144A patent/PE20060825A1/es active IP Right Grant
- 2005-09-28 GT GT200500269A patent/GT200500269A/es unknown
- 2005-09-28 PE PE2009000511A patent/PE20091586A1/es not_active Application Discontinuation
- 2005-09-28 PE PE2009000509A patent/PE20091584A1/es active IP Right Grant
- 2005-09-28 PE PE2009000510A patent/PE20091585A1/es active IP Right Grant
- 2005-09-29 SV SV2005002243A patent/SV2006002243A/es active IP Right Grant
- 2005-10-04 HN HN2005000768A patent/HN2005000768A/es unknown
2007
- 2007-03-20 IL IL182046A patent/IL182046A0/en active IP Right Grant
- 2007-03-26 CU CU20070069A patent/CU23754B7/es active IP Right Grant
- 2007-03-27 ZA ZA200702511A patent/ZA200702511B/en unknown
- 2007-03-28 EC EC2007007357A patent/ECSP077357A/es unknown
- 2007-03-30 MA MA29788A patent/MA28883B1/fr unknown
- 2007-04-26 NO NO20072173A patent/NO339647B1/no unknown
2012
- 2012-11-02 JP JP2012242831A patent/JP5583190B2/ja not_active Expired - Lifetime
2015
- 2015-03-17 CY CY20151100268T patent/CY1116126T1/el unknown

Also Published As

Publication number	Publication date
HN2005000768A (es)	2010-09-17
JP2008514657A (ja)	2008-05-08
CU20070069A7 (es)	2010-11-27
ZA200702511B (en)	2008-07-30
CA2581835C (fr)	2012-12-18
HRP20150295T1 (hr)	2015-05-22
NZ554119A (en)	2010-07-30
IL182046A0 (en)	2007-07-24
GT200500269A (es)	2006-05-11
KR101263032B1 (ko)	2013-05-09
TW200626551A (en)	2006-08-01
PE20091585A1 (es)	2009-10-31
SI1797037T1 (sl)	2015-06-30
CU23754B7 (es)	2012-01-31
UY29143A1 (es)	2006-04-28
DK1797037T3 (en)	2015-03-30
PT1797037E (pt)	2015-03-17
CY1116126T1 (el)	2017-02-08
KR20070058676A (ko)	2007-06-08
PE20091586A1 (es)	2009-10-31
PE20060825A1 (es)	2006-10-20
BRPI0515944B1 (pt)	2021-11-09
CN101052619A (zh)	2007-10-10
MY149873A (en)	2013-10-31
PL1797037T3 (pl)	2015-07-31
UA90691C2 (en)	2010-05-25
NO20072173L (no)	2007-06-14
TWI382973B (zh)	2013-01-21
ECSP077357A (es)	2007-04-26
AU2005289099B2 (en)	2012-07-19
EP1797037B1 (fr)	2014-12-17
JP5583190B2 (ja)	2014-09-03
US8124782B2 (en)	2012-02-28
HK1113484A1 (en)	2008-10-03
JP2013067625A (ja)	2013-04-18
EP1797037A1 (fr)	2007-06-20
ES2532377T3 (es)	2015-03-26
CA2581835A1 (fr)	2006-04-06
CN101052619B (zh)	2012-02-22
BRPI0515944A (pt)	2008-08-12
AU2005289099A1 (en)	2006-04-06
NO339647B1 (no)	2017-01-16
AR053973A1 (es)	2007-05-30
US20080262236A1 (en)	2008-10-23
SG155997A1 (en)	2009-10-29
PE20091584A1 (es)	2009-10-28
PE20091587A1 (es)	2009-11-05
WO2006034796A1 (fr)	2006-04-06
SV2006002243A (es)	2006-10-13
DOP2005000183A (es)	2006-03-31

Publication	Publication Date	Title
SG155997A1 (en)	2009-10-29	Process for the preparation of 4-{4-[({[4-chloro-3- (trifluoromethyl)phenyl]amino}carbonyl)amino]phenoxy}-n- methylpyridine-2-carboxamide
UA91520C2 (en)	2010-08-10	Thermodynamically stable form of tosylate
PL2097381T3 (pl)	2013-11-29	Jednowodzian 4-[4-({[4-chloro-3-(trifluorometylo)fenylo)]karbamoilo}amino)-3-fluorofenoksy]-N-metylopirydyno-2-karboksyamidu
LTC3170818I2 (lt)	2023-05-25	Kietos 3-(6-(1-(2,2-difluorbenzo[d][1,3]dioksol-5-il)ciklopropankarboksamido)-3-metilpiridin-2-il)benzoinės rūgšties formos
IL175933A (en)	2010-12-30	Crystalline form of the salt of 4-(3-chloro-4-(cyclopropylaminocarbonyl)aminophenoxy)-7-methoxy-6-quinolinecarboxamide or the solvate of the salt, a pharmaceutical composition comprising the same and a process for preparing the same
EP1830956A4 (fr)	2012-07-11	Materiaux catalytiques et procede pour leur preparation
SG10201501221UA (en)	2015-04-29	Process for the preparation of 4- {4-[({[4 -chloro-3 -(trifluoromethyl)-phenyl]amino}carbonyl)amino]-3-fluorophenoxy}-n-methylpyridine-2-carboxamide, its salts and monohydrate
DK1973429T3 (da)	2013-10-28	Proteinhydrolysater og fremgangsmåde til fremstilling
DK1760156T3 (da)	2013-03-18	Materialer og fremgangsmåder til effektiv mælkesyrefremstilling
ZA200801854B (en)	2009-08-26	Method of preparing esomeprazole and salts thereof
IL182996A0 (en)	2007-08-19	Process for preparing quinoline compounds and products obtained therefrom
DE602006014300D1 (de)	2010-06-24	Verfahren und system für medienunabhängiges handover unter verwendung des oamp-protokolls
TWI347947B (en)	2011-09-01	Process for preparing [4-(1,3,4-oxadiazol-2-yl)phenyl] boronic acid and use thereof
EP1812906A4 (fr)	2014-08-13	Appareil d'edition pleine page, procede d'edition pleine page et programme d'edition pleine page
FI20050422A0 (fi)	2005-04-22	Menetelmä ja laitteisto naulalevyristikoiden valmistamiseksi
IL172169A0 (en)	2009-02-11	Processes for preparing (2s) - 3 - (4 - {2 - [amino] - 2 - oxoethoxy}
FR2886650B1 (fr)	2007-08-24	Procede d'enrichissement de residus lignocellulosiques en proteines de levure
FR2876689B1 (fr)	2008-02-22	Nouveau procede et intermediaires de preparation de derives de n-(1-benzhydryl-azetidin-3-yl)-n-phenyl-methylsulfonamide
FR2886102B1 (fr)	2007-07-27	Procede de fabrication ou de pre-assemblage d'un filet, notamment un filet de peche, filet de peche ainsi obtenu
FR2879895B1 (fr)	2007-03-16	Procede de fabrication ou pre-assemblage d'un filet, notamment un filet de peche, filet de peche ainsi obtenu
FI20045228L (fi)	2005-12-18	Menetelmä, laite ja tietokoneohjelmatuote paikkasidonnaisen tiedon käsittelyyn
FR2860956B1 (fr)	2006-02-17	Additif nutritionnel pour animaux, procede de preparation et applications
HK1088300A (en)	2006-11-03	Processes for preparing (2s)-3-(4-{2-[amino]-2-oxoethoxy}phenyl)-2-ethoxypropanoic acid derivatives
ZA200702609B (en)	2008-11-26	Process for making phenoxy benzamide compounds
HK1107334A (en)	2008-04-03	Process for making phenoxy benzamide compounds